Method for diagnosing diabetes in a mammal

Abstract

Provided are mammalian secreted and non-secreted diabetes mediating proteins, including protective and deleterious diabetes-mediating proteins, as well as polynucleotides encoding same, drug screening methods for identifying a test compound capable of altering the expression of a diabetes-mediating protein, and methods of preventing or ameliorating diabetes by administering a compound capable of the expression of a diabetes-mediating protein.

1 . A method for diagnosing diabetes in a mammal, such as a human, the method comprising determining the presence, absence or level of expression of at least one marker protein in a biological sample from said mammal, wherein the marker protein is creatin Kinase B. 
     
     
         2 . A method according to  claim 1 , wherein the method comprises establishing the increased expression of the marker protein. 
     
     
         3 . A method according to  claim 1 , wherein the biological sample is selected from the group consisting of urine, blood, saliva, lymphatic fluids, and tissue. 
     
     
         4 . A method according to  claim 3 , wherein the tissue is pancreatic tissue. 
     
     
         5 . A method for determining the predisposition for diabetes in a mammal,
 such as a human, the method comprising determining the presence, absence or relative level in a biological sample originating from the mammal of at least one marker protein, wherein the marker protein is creatin Kinase B.   
     
     
         6 . A method for determining the predisposition in a human for diabetes, the method comprising:
 a) determining the increased expression of a marker protein in a biological sample originating from the human, wherein said marker protein creatin Kinase B;   b) determining the decreased expression in a biological sample from the human of at least a marker protein, said marker protein being creatin Kinase B; or   c) combinations of the determinations in a) and b).   
     
     
         7 . A method according to  claim 1 , wherein the at least one marker protein is selected from the group consisting of:
 a) one or more proteins present in a significantly lower or significantly higher amount on a polyacrylamide gel of proteins from said biological sample in relation to a control;   b) one or more proteins present on a polyacrylamide gel of proteins from said biological sample and absent on polyacrylamide gel of proteins of a control; and   c) one or more proteins absent on a polyacrylamide gel of proteins from said biological sample and present on polyacrylamide gel of proteins of a control.   
     
     
         8 - 29 . (canceled) 
     
     
         30 . The method of  claim 1 , wherein the level of expression of the creatin Kinase-B is determined by measuring the amount of binding to an antibody for said creatin Kinase-B. 
     
     
         31 . The method according to claim  33 , wherein the antibody is a polyclonal antibody. 
     
     
         32 . The method according to claim  33 , wherein the antibody is a monoclonal antibody.